Top

Published in:

01-07-2014 | Educational Review

The nephrotic syndrome: pathogenesis and treatment of edema formation and secondary complications

Authors: Melissa A. Cadnapaphornchai, Oleksandra Tkachenko, Dmitry Shchekochikhin, Robert W. Schrier

Published in: Pediatric Nephrology | Issue 7/2014

Abstract

Nephrotic syndrome is an important clinical condition affecting both children and adults. Studies suggest that the pathogenesis of edema in individual patients may occur via widely variable mechanisms, i.e., intravascular volume underfilling versus overfilling. Managing edema should therefore be directed to the underlying pathophysiology. Nephrotic syndrome is also associated with clinically important complications related to urinary loss of proteins other than albumin. This educational review focuses on the pathophysiology and management of edema and secondary complications in patients with nephrotic syndrome.

Epstein AA (1952) Concerning the causation of edema in chronic parenchymatous nephritis; method for its alleviation. Am J Med 13:556–561CrossRefPubMed

Meltzer JI, Keim HJ, Laragh JH, Sealey JE, Jan KM, Chien S (1979) Nephrotic syndrome: vasoconstriction and hypervolemic types indicated by renin-sodium profiling. Ann Intern Med 91:688–696CrossRefPubMed

Deegens JKJ, Schrier RW, Wetzels JFM (2012) The nephrotic syndrome. In: Schrier RW (ed) Diseases of the kidney, 9th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1997–2011

Van de Walle JG, Donckerwolcke RA, Greidanus TB, Joles JA, Koomans HA (1996) Renal sodium handling in children with nephrotic relapse: relation to hypovolaemic symptoms. Nephrol Dial Transplant 11:2202–2208CrossRefPubMed

Oliver WJ, Owings CL (1967) Sodium excretion in the nephrotic syndrome. Relation to serum albumin concentration, glomerular filtration rate, and aldosterone excretion rate. Am J Dis Child 113:352–362CrossRefPubMed

Schrier RW (1988) Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1). N Engl J Med 319:1065–1072CrossRefPubMed

O’Hare JP, Roland JM, Walters G, Corrall RJ (1986) Impaired sodium excretion in response to volume expansion induced by water immersion in insulin-dependent diabetes mellitus. Clin Sci (Lond) 71:403–409

Bojestig M, Nystrom FH, Arnqvist HJ, Ludvigsson J, Karlberg BE (2000) The renin-angiotensin-aldosterone system is suppressed in adults with Type 1 diabetes. J Renin-Angiotensin-Aldosterone Syst 1:353–356CrossRefPubMed

Usberti M, Federico S, Meccariello S, Cianciaruso B, Balletta M, Pecoraro C, Sacca L, Ungaro B, Pisanti N, Andreucci VE (1984) Role of plasma vasopressin in the impairment of water excretion in nephrotic syndrome. Kidney Int 25:422–429CrossRefPubMed

10.

Dorhout Mees EJ, Koomans HA (1995) Understanding the nephrotic syndrome: what’s new in a decade? Nephron 70:1–10CrossRefPubMed

11.

Gur A, Adefuin PY, Siegel NJ, Hayslett JP (1976) A study of the renal handling of water in lipoid nephrosis. Pediatr Res 10:197–201CrossRefPubMed

12.

Schrier RW, Fassett RG (1998) A critique of the overfill hypothesis of sodium and water retention in the nephrotic syndrome. Kidney Int 53:1111–1117CrossRefPubMed

13.

Brown EA, Markandu ND, Sagnella GA, Jones BE, MacGregor GA (1984) Lack of effect of captopril on the sodium retention of the nephrotic syndrome. Nephron 37:43–48CrossRefPubMed

14.

Shapiro MD, Hasbargen J, Hensen J, Schrier RW (1990) Role of aldosterone in the sodium retention of patients with nephrotic syndrome. Am J Nephrol 10:44–48CrossRefPubMed

15.

Usberti M, Gazzotti RM, Poiesi C, D’Avanzo L, Ghielmi S (1995) Considerations on the sodium retention in nephrotic syndrome. Am J Nephrol 15:38–47CrossRefPubMed

16.

Kapur G, Valentini RP, Imam AA, Mattoo TK (2009) Treatment of severe edema in children with nephrotic syndrome with diuretics alone–a prospective study. Clin J Am Soc Nephrol 4:907–913PubMedCentralCrossRefPubMed

17.

Jespersen B, Eiskjaer H, Mogensen CE, Sorensen SS, Pedersen EB (1995) Reduced natriuretic effect of atrial natriuretic peptide in nephrotic syndrome: a possible role of decreased cyclic guanosine monophosphate. Nephron 71:44–53CrossRefPubMed

18.

Valentin JP, Qiu C, Muldowney WP, Ying WZ, Gardner DG, Humphreys MH (1992) Cellular basis for blunted volume expansion natriuresis in experimental nephrotic syndrome. J Clin Invest 90:1302–1312PubMedCentralCrossRefPubMed

19.

Lee EY, Humphreys MH (1996) Phosphodiesterase activity as a mediator of renal resistance to ANP in pathological salt retention. Am J Physiol 271:F3–F6PubMed

20.

Kleyman TR, Myerburg MM, Hughey RP (2006) Regulation of ENaCs by proteases: an increasingly complex story. Kidney Int 70:1391–1392CrossRefPubMed

21.

Planes C, Caughey GH (2007) Regulation of the epithelial Na+ channel by peptidases. Curr Top Dev Biol 78:23–46PubMedCentralCrossRefPubMed

22.

Svenningsen P, Bistrup C, Friis UG, Bertog M, Haerteis S, Krueger B, Stubbe J, Jensen ON, Thiesson HC, Uhrenholt TR, Jespersen B, Jensen BL, Korbmacher C, Skott O (2009) Plasmin in nephrotic urine activates the epithelial sodium channel. J Am Soc Nephrol 20:299–310PubMedCentralCrossRefPubMed

23.

Andersen RF, Buhl KB, Jensen BL, Svenningsen P, Friis UG, Jespersen B, Rittig S (2013) Remission of nephrotic syndrome diminishes urinary plasmin content and abolishes activation of ENaC. Pediatr Nephrol 28:1227–1234CrossRefPubMed

24.

Radhakrishnan J, Cattran DC (2012) The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines–application to the individual patient. Kidney Int 82:840–856CrossRefPubMed

25.

Lombel RM, Gipson DS, Hodson EM (2013) Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol 28:415–426CrossRefPubMed

26.

Lombel RM, Hodson EM, Gipson DS (2013) Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO. Pediatr Nephrol 28:409–414CrossRefPubMed

27.

KDIGO Work Group (2013) KDIGO 2012 clinical practice guidelines for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1–150CrossRef

28.

Engle MA, Lewy JE, Lewy PR, Metcoff J (1978) The use of furosemide in the treatment of edema in infants and children. Pediatrics 62:811–818PubMed

29.

Prandota J (1983) Pharmacokinetics of furosemide urinary elimination by nephrotic children. Pediatr Res 17:141–147CrossRefPubMed

30.

Agarwal R, Gorski JC, Sundblad K, Brater DC (2000) Urinary protein binding does not affect response to furosemide in patients with nephrotic syndrome. J Am Soc Nephrol 11:1100–1105PubMed

31.

Bansal S, Lindenfeld J, Schrier RW (2009) Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail 2:370–376CrossRefPubMed

32.

Ellison DH, Velazquez H, Wright FS (1989) Adaptation of the distal convoluted tubule of the rat. Structural and functional effects of dietary salt intake and chronic diuretic infusion. J Clin Invest 83:113–126PubMedCentralCrossRefPubMed

33.

Abdallah JG, Schrier RW, Edelstein C, Jennings SD, Wyse B, Ellison DH (2001) Loop diuretic infusion increases thiazide-sensitive Na(+)/Cl(−)-cotransporter abundance: role of aldosterone. J Am Soc Nephrol 12:1335–1341PubMed

34.

Loon NR, Wilcox CS, Unwin RJ (1989) Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int 36:682–689CrossRefPubMed

35.

Lang GR, Westenfelder C, Nascimento L, Dhupelia VB, Arruda JA, Kane RE (1977) Metolazone and spironolactone in cirrhosis and the nephrotic syndrome. Clin Pharmacol Ther 21:234–243PubMed

36.

Schapel GJ, Edwards DG, Robinson J (1975) Potassium-sparing effect of amiloride in a diuretic factorial study in man. Clin Exp Pharmacol Physiol 2:277–287CrossRefPubMed

37.

Davison AM, Lambie AT, Verth AH, Cash JD (1974) Salt-poor human albumin in management of nephrotic syndrome. Br Med J 1:481–484PubMedCentralCrossRefPubMed

38.

Gilles R, den Heijer M, Ross AH, Sweep FC, Hermus AR, Wetzels JF (2008) Thyroid function in patients with proteinuria. Neth J Med 66:483–485PubMed

39.

Afroz S, Khan AH, Roy DK (2011) Thyroid function in children with nephrotic syndrome. Mymensingh Med J 20:407–411PubMed

40.

Dagan A, Cleper R, Krause I, Blumenthal D, Davidovits M (2012) Hypothyroidism in children with steroid-resistant nephrotic syndrome. Nephrol Dial Transplant 27:2171–2175CrossRefPubMed

41.

Kapoor K, Saha A, Dubey NK, Goyal P, Suresh CP, Batra V, Upadhayay AD (2013) Subclinical non-autoimmune hypothyroidism in children with steroid resistant nephrotic syndrome. Clin Exp Nephrol. doi:10.1007/s10157-013-0800-1

42.

Hancock DE, Onstad JW, Wolf PL (1976) Transferrin loss into the urine with hypochromic, microcytic anemia. Am J Clin Pathol 65:73–78PubMed

43.

Feinstein S, Becker-Cohen R, Algur N, Raveh D, Shalev H, Shvil Y, Frishberg Y (2001) Erythropoietin deficiency causes anemia in nephrotic children with normal kidney function. Am J Kidney Dis 37:736–742CrossRefPubMed

44.

Barragry JM, France MW, Carter ND, Auton JA, Beer M, Boucher BJ, Cohen RD (1977) Vitamin-D metabolism in nephrotic syndrome. Lancet 2:629–632CrossRefPubMed

45.

Malluche HH, Goldstein DA, Massry SG (1979) Osteomalacia and hyperparathyroid bone disease in patients with nephrotic syndrome. J Clin Invest 63:494–500PubMedCentralCrossRefPubMed

46.

Mahmoodi BK, ten Kate MK, Waanders F, Veeger NJ, Brouwer JL, Vogt L, Navis G, van der Meer J (2008) High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation 117:224–230CrossRefPubMed

47.

Singhal R, Brimble KS (2006) Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thromb Res 118:397–407CrossRefPubMed

48.

Kerlin BA, Blatt NB, Fuh B, Zhao S, Lehman A, Blanchong C, Mahan JD, Smoyer WE (2009) Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: a Midwest Pediatric Nephrology Consortium (MWPNC) study. J Pediatr 155(105–10):110

49.

Glassock RJ (2007) Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J Am Soc Nephrol 18:2221–2225CrossRefPubMed

50.

Pincus KJ, Hynicka LM (2013) Prophylaxis of thromboembolic events in patients with nephrotic syndrome. Ann Pharmacother 47:725–734CrossRefPubMed

51.

Ogi M, Yokoyama H, Tomosugi N, Hisada Y, Ohta S, Takaeda M, Wada T, Naito T, Ikeda K, Goshima S (1994) Risk factors for infection and immunoglobulin replacement therapy in adult nephrotic syndrome. Am J Kidney Dis 24:427–436PubMed

52.

Committee on Infectious Diseases AAP (2012) Report of the committee on infectious diseases. In: Pickering LK (ed) Online electronic medical library, 29th edn. American Academy of Pediatrics, Elk Grove Village

53.

Liakou CD, Askiti V, Mitsioni A, Stefanidis CJ, Theodoridou MC, Spoulou VI (2011) Safety, immunogenicity and kinetics of immune response to 7-valent pneumococcal conjugate vaccine in children with idiopathic nephrotic syndrome. Vaccine 29(40):6834–6837

54.

Ulinski T, Leroy S, Dubrel M, Danon S, Bensman A (2008) High serological response to pneumococcal vaccine in nephrotic children at disease onset on high-dose prednisone. Pediatr Nephrol 23(7):1107–1113

55.

Joven J, Villabona C, Vilella E, Masana L, Alberti R, Valles M (1990) Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 323:579–584CrossRefPubMed

56.

Wanner C, Rader D, Bartens W, Kramer J, Brewer HB, Schollmeyer P, Wieland H (1993) Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med 119:263–269CrossRefPubMed

57.

Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH (1993) The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 44:638–642CrossRefPubMed

58.

Silva JM, Oliveira EA, Marino VS, Oliveira JS, Torres RM, Ribeiro AL, Simal CJ, Ribeiro MC (2002) Premature acute myocardial infarction in a child with nephrotic syndrome. Pediatr Nephrol 17:169–172CrossRefPubMed

59.

Hopp L, Gilboa N, Kurland G, Weichler N, Orchard TJ (1994) Acute myocardial infarction in a young boy with nephrotic syndrome: a case report and review of the literature. Pediatr Nephrol 8:290–294CrossRefPubMed

60.

Lechner BL, Bockenhauer D, Iragorri S, Kennedy TL, Siegel NJ (2004) The risk of cardiovascular disease in adults who have had childhood nephrotic syndrome. Pediatr Nephrol 19:744–748CrossRefPubMed

61.

Kniazewska MH, Obuchowicz AK, Wielkoszynski T, Zmudzinska-Kitczak J, Urban K, Marek M, Witanowska J, Sieron-Stoltny K (2009) Atherosclerosis risk factors in young patients formerly treated for idiopathic nephrotic syndrome. Pediatr Nephrol 24:549–554CrossRefPubMed

62.

Falaschi F, Ravelli A, Martignoni A, Migliavacca D, Sartori M, Pistorio A, Perani G, Martini A (2000) Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum 43:1405–1409CrossRefPubMed

63.

Hutchison FN (1993) Hormonal modulation of proteinuria in the nephrotic syndrome. Am J Nephrol 13:337–346CrossRefPubMed

Title: The nephrotic syndrome: pathogenesis and treatment of edema formation and secondary complications
Authors: Melissa A. Cadnapaphornchai
Oleksandra Tkachenko
Dmitry Shchekochikhin
Robert W. Schrier
Publication date: 01-07-2014
Publisher: Springer Berlin Heidelberg
Published in: Pediatric Nephrology / Issue 7/2014
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-013-2567-8

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The nephrotic syndrome: pathogenesis and treatment of edema formation and secondary complications

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2014

Protein energy wasting in children with chronic kidney disease

Desmopressin alone versus desmopressin and an anticholinergic in the first-line treatment of primary monosymptomatic nocturnal enuresis: a multicenter study

Fetal renin-angiotensin-system blockade syndrome: renal lesions

Health-related quality of life of children and adolescents with CKD stages 4–5 and their caregivers

Psychosocial support for children and families requiring renal replacement therapy

Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy